Skip to main content
. 2020 Jan 17;323(5):423–431. doi: 10.1001/jama.2019.22176

Table 2. Primary and Secondary Outcomes.

Outcomes Intervention (n = 107) Control (n = 104) Difference (95% CI) P Value
Primary Outcome
Time alive and free of vasopressors, median (IQR), h 122.1 (76.3 to 145.4) 124.6 (82.1 to 147.0) –0.6 (–8.3 to 7.2)a .83
Secondary Outcomes
28-d Mortality, No. (%) 24 (22.6) [n = 106] 21 (20.4) [n = 103] 2.3 (–8.9 to 13.4) .69
90-d Mortality, No. (%) 30 (28.6) [n = 105] 25 (24.5) [n = 102] 4.1 (–8.0 to 16.1) .51
ICU mortality, No. (%) 21 (19.6) 19 (18.3) 1.4 (–9.2 to 11.9) .80
Hospital mortality, No. (%) 25 (23.4) 21 (20.4) [n = 103] 3.0 (–8.2 to 14.1) .60
28-d Cumulative vasopressor-free days, median (IQR) 25.6 (17.8 to 26.8) [n = 106] 25.8 (19.6 to 26.8) [n = 103] –0.2 (–1.7 to 1.2) .66
28-d Cumulative mechanical ventilation-free days, median (IQR) 25.3 (5.2 to 28.0) [n = 106] 24.8 (9.5 to 28.0) [n = 103] 0.4 (–2.6 to 3.4) .73
28-d Renal replacement therapy–free days, median (IQR) 28.0 (23.5 to 28.0) [n = 105] 28.0 (21.0 to 28.0) [n = 103] 0.0 (–0.6 to 0.6) .71
Change in SOFA score at day 3, median (IQR)b –2 (–4 to 0) [n = 82] –1 (–3 to 0) [n = 75] –1.0 (–1.9 to –0.1) .02
28-d ICU-free days, median (IQR) 21.9 (0 to 25.8) [n = 106] 22.1 (3.9 to 25.8) [n = 103] –0.2 (–4.1 to 3.7) .66
Hospital length of stay, median (IQR), d 12.3 (6.2 to 26.0) 12.3 (6.2 to 26.1) [n = 103] 0.0 (–4.9 to 4.9) .75
Prespecified Exploratory Outcome
Acute kidney injury, No. (%)
Stage 1 18 (16.8) 14 (13.5) 3.4 (–6.3 to 13.0) .80
Stage 2 18 (16.8) 22 (21.2) –4.3 (–14.9 to 6.2)
Stage 3 39 (36.4) 39 (37.5) –1.1 (–14.1 to 12.0)

Abbreviations: ICU, intensive care unit; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment.

a

Hodges-Lehmann estimate, the median of all paired differences between observations in the intervention group minus the control group.

b

Change in SOFA score: score at day 3 minus score at baseline.